Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ARO-MAPT-SC
ARO-MAPT · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ARO-MAPT-SC | EXPERIMENTAL | ARO-MAPT-SC injection |
| Placebo | PLACEBO_COMPARATOR | Sterile normal saline (0.9%) |
| Name | Type | Description |
|---|---|---|
| ARO-MAPT-SC | DRUG | • single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection |
| Placebo | DRUG | • calculated volume to match active treatment by SC administration |
Inclusion Criteria (All Participants): * Body mass index between 18.0 and 35.0 kilograms (kg)/square meter (m\^2) at Screening * Not pregnant or breast-feeding * Able and willing to provide written informed consent prior to the performance of any study specific procedures * Participants of childbea...
Top 20 of 23 competitors
ARO-MAPT is an investigational small molecule being developed for Alzheimer Disease. It is currently in Phase 1 clinical development, studied in healthy participants and participants with early Alzheimer's Disease. The drug is administered subcutaneously and is being evaluated in a randomized, double-blind, placebo-controlled trial.
ARO-MAPT targets the MAPT gene, which encodes the tau protein. By targeting MAPT, the drug aims to reduce tau protein production, a key pathological feature in Alzheimer's Disease. This mechanism is being investigated in early-stage clinical trials for its potential to modify the disease course.
ARO-MAPT is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker ARWR. The company is conducting a Phase 1 clinical trial to evaluate the safety and tolerability of ARO-MAPT in healthy volunteers and patients with early Alzheimer's Disease.
ARO-MAPT is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and pharmacokinetics in healthy individuals and those with early Alzheimer's Disease.
ARO-MAPT is being studied in a single Phase 1 clinical trial registered as NCT07221344. This trial, titled 'Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease,' is recruiting 112 participants in Canada and New Zealand. The study is randomized, double-blind, and placebo-controlled.
Yes, ARO-MAPT is also known as ARO-MAPT-SC. The '-SC' suffix indicates the subcutaneous route of administration used in the clinical trial. Both names refer to the same investigational drug being developed by Arrowhead Pharmaceuticals for Alzheimer's Disease.